ID   IIB-BR-G
AC   CVCL_B410
SY   Instituto de Investigaciones Bioquimicas-BReast cancer-G
DR   Cosmic; 1507366
DR   Wikidata; Q54897420
RX   PubMed=1661624;
RX   PubMed=9620446;
RX   PubMed=21308409;
CC   Population: Caucasian.
CC   Doubling time: ~30 hours (PubMed=1661624).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   50Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 11
//
RX   PubMed=1661624; DOI=10.1007/BF01975204;
RA   Bover L.C., Barrio M.M., Slavutsky I., Bravo A.I., Quintans C.,
RA   Bagnati A., Lema B., Schiaffi J., Yomha R., Mordoh J.;
RT   "Description of a new human breast cancer cell line, IIB-BR-G,
RT   established from a primary undifferentiated tumor.";
RL   Breast Cancer Res. Treat. 19:47-56(1991).
//
RX   PubMed=9620446;
RA   Bover L.C., Barrio M.M., Bravo A.I., Slavutsky I., Larripa I., Bolondi A.,
RA   Ayala M., Mordoh J.;
RT   "The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos
RT   oncogenes in vitro and is spontaneously metastatic in vivo.";
RL   Cell. Mol. Biol. 44:493-504(1998).
//
RX   PubMed=21308409; DOI=10.1007/s10549-011-1360-2;
RA   Roberti M.P., Barrio M.M., Bravo A.I., Rocca Y.S., Arriaga J.M.,
RA   Bianchini M., Mordoh J., Levy E.M.;
RT   "IL-15 and IL-2 increase cetuximab-mediated cellular cytotoxicity
RT   against triple negative breast cancer cell lines expressing EGFR.";
RL   Breast Cancer Res. Treat. 130:465-475(2011).
//